HLA DQA1*05 and risk of anti-TNF treatment failure and anti-drug antibody development in children with Crohn's Disease: HLA DQA1*05 and Pediatric Crohn's Disease.
Carolina Digital Repository (University of North Carolina at Chapel Hill) · 19.10.2025
DOI: 10.17615/j06w-4z76 ↗Kurz gefasst
Fachartikel in der Zeitschrift Carolina Digital Repository (University of North Carolina at Chapel Hill), erschienen am 19.10.2025. Verfasst von Jess L. Kaplan und 32 weiteren Autor:innen.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
OBJECTIVES: HLA DQA1*05 has been associated with the development of anti-drug antibodies (ADA) to tumor necrosis factor antagonists (anti-TNF) and treatment failure among adults with Crohn's disease (CD). However, findings from other studies have been inconsistent with limited pediatric data. METHODS: We analyzed banked serum from patients with CD < 21 years of age enrolled in COMBINE, a multi-center, prospective randomized trial of anti-TNF monotherapy vs. combination with methotrexate. The primary outcome was a composite of factors indicative of treatment failure. The secondary outcome was ADA development. RESULTS: A trend towards increased treatment failure among HLA DQA1*05 positive participants was not significant (HR 1.58, 95% CI 0.95-2.62; p=0.08). After stratification by HLA DQA1*05 and by methotrexate vs. placebo, patients who were HLA DQA1*05 negative and assigned to methotrexate experienced less treatment failures than HLA DQA1*05 positive patients on placebo (HR 0.31, 95% CI 0.13-0.70; p=0.005).A trend toward increased ADA development among HLA DQA1*05 positive participants was not significant (odds ratio [OR] 1.96, 95% CI 0.90-4.31, p=0.09). After further stratification, HLA DQA1*05 negative participants assigned to methotrexate were less likely to develop ADA relative to HLA DQA1*05 positive patients on placebo (OR 0.12, 95% CI 0.03-0.55; p=0.008). CONCLUSIONS: In a randomized trial of children with CD initiating anti-TNF, 40% were HLA DQ-A1*05 positive, which was associated with a trend toward increased risk of both treatment failure and ADA. These risks were mitigated, but not eliminated, by adding oral methotrexate. HLA DQ-A1*05 is an important biomarker for prognosis and risk stratification.
Schlagwörter
Zitieren
APA
Kaplan, J. L., Moses, J., Saeed, S. A., Olano, K. K., Firestine, A. M., Bousvaros, A., Molle‐Rios, Z., Pashankar, D. S., Benkov, K. J., Cabrera, J. M., Gulati, A., Adler, Jeremy, Ammoury, R., Samson, C. M., Linville, T. M., Galanko, J. A., Wali, P. D., Pitch, L., …, & Minar, P. (2025). HLA DQA1*05 and risk of anti-TNF treatment failure and anti-drug antibody development in children with Crohn's Disease: HLA DQA1*05 and Pediatric Crohn's Disease. Carolina Digital Repository (University of North Carolina at Chapel Hill). https://doi.org/10.17615/j06w-4z76
Vancouver
Kaplan JL, Moses J, Saeed SA, Olano KK, Firestine AM, Bousvaros A, et al. HLA DQA1*05 and risk of anti-TNF treatment failure and anti-drug antibody development in children with Crohn's Disease: HLA DQA1*05 and Pediatric Crohn's Disease. Carolina Digital Repository (University of North Carolina at Chapel Hill). 2025. doi:10.17615/j06w-4z76
BibTeX
@article{Kaplan2025,
author = {Kaplan, Jess L. and Moses, Jonathan and Saeed, Shehzad Ahmed and Olano, Kelly K. and Firestine, Ann M. and Bousvaros, Athos and Molle‐Rios, Zarela and Pashankar, Dinesh S. and Benkov, Keith J. and Cabrera, José M and Gulati, Ajay and Adler and Jeremy and Ammoury, Rana and Samson, Charles M. and Linville, Tiffany M. and Galanko, Joseph A. and Wali, Prateek D. and Pitch, Lisa and Steiner, Steven J. and Strople, Jennifer A. and Chun, Kelly and Sandberg, Kelly and Boyle, Brendan and Kappelman, Michael D. and Sullivan, Jillian S. and Ebach, Dawn R. and Dorsey, Jill M. and Jester, Traci and Leibowitz, Ian and Herfarth, Hans H. and Margolis, Peter A. and Minar, Phillip},
title = {HLA DQA1*05 and risk of anti-TNF treatment failure and anti-drug antibody development in children with Crohn's Disease: HLA DQA1*05 and Pediatric Crohn's Disease},
journal = {Carolina Digital Repository (University of North Carolina at Chapel Hill)},
year = {2025},
doi = {10.17615/j06w-4z76}
}
EUVIMED